human aurkb protein Search Results


aurkb (aurora b) recombinant human protein  (Thermo Fisher)
N/A
The Aurora kinases associate with microtubules during chromosome movement and segregation. AURKB (Aurora B) localizes to microtubules near kinetochores, specifically to the specialized microtubules called K-fibers.
   Buy from Supplier
human aurkb protein lysate  (Innovative Research Inc)
N/A
Human AURKB Protein Lysate 20ug from Innovative Research is provided as a Lyophilized powder. This is a Recombinant Protein Lysate produced in HEK293T cells. This protein lysate can be reconsituted using SDS Sample Buffer. Once
   Buy from Supplier
aurora b protein  (Boster Bio)
90
Boster Bio aurora b protein
Aurora B Protein, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aurkb+protein/Human+Aurora+B+Recombinant+Protein/pm33219625-38-13-23
Average 90 stars, based on 1 article reviews
aurora b protein - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
aurkb  (Human Protein Atlas)
86
Human Protein Atlas aurkb
Two CREB1 target gene signatures correlate with outcomes (A) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that <t>AURKB,</t> <t>CDC20,</t> CENPA, GGH, H2AC20, MND1, PRC1, and PSPH positively correlate with each other. (B) Expression of each of the eight CREB1-activated genes was dichotomized into high or low groups based on the median expression across all patients, and assigned a score of 1 (high) or 0 (low). A composite gene score (GS) was calculated as the sum of individual gene scores, yielding values from 0 to 8 . Patients with GSs 7–8 were defined as GS high and those with GSs 0–6 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-activated GS-high patients had significantly shorter OS ( p = 0.041) compared with GS-low patients. (C) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that NR2F1 positively correlated with the CREB1-repressed genes while negatively correlated with the CREB1-activated genes. (D) The 8 CREB1-repressed genes were scored similarly as described in (B). Patients with GSs 5–8 were defined as GS high, and those with GSs 0–4 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-repressed GS-high patients had significantly prolonged OS ( p = 0.040) compared with GS-low patients.
Aurkb, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+aurkb+protein/aurkb/pmc13138062-325-24-53
Average 86 stars, based on 1 article reviews
aurkb - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
aurora b aurkb nm 004217 human recombinant protein  (OriGene)
N/A
Recombinant protein of human aurora kinase B AURKB
   Buy from Supplier

Image Search Results


Two CREB1 target gene signatures correlate with outcomes (A) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that AURKB, CDC20, CENPA, GGH, H2AC20, MND1, PRC1, and PSPH positively correlate with each other. (B) Expression of each of the eight CREB1-activated genes was dichotomized into high or low groups based on the median expression across all patients, and assigned a score of 1 (high) or 0 (low). A composite gene score (GS) was calculated as the sum of individual gene scores, yielding values from 0 to 8 . Patients with GSs 7–8 were defined as GS high and those with GSs 0–6 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-activated GS-high patients had significantly shorter OS ( p = 0.041) compared with GS-low patients. (C) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that NR2F1 positively correlated with the CREB1-repressed genes while negatively correlated with the CREB1-activated genes. (D) The 8 CREB1-repressed genes were scored similarly as described in (B). Patients with GSs 5–8 were defined as GS high, and those with GSs 0–4 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-repressed GS-high patients had significantly prolonged OS ( p = 0.040) compared with GS-low patients.

Journal: iScience

Article Title: Dormancy exit correlates with CREB1 reactivation that is a potential target to overcome endocrine therapy resistance in ER + breast cancer cells

doi: 10.1016/j.isci.2026.115610

Figure Lengend Snippet: Two CREB1 target gene signatures correlate with outcomes (A) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that AURKB, CDC20, CENPA, GGH, H2AC20, MND1, PRC1, and PSPH positively correlate with each other. (B) Expression of each of the eight CREB1-activated genes was dichotomized into high or low groups based on the median expression across all patients, and assigned a score of 1 (high) or 0 (low). A composite gene score (GS) was calculated as the sum of individual gene scores, yielding values from 0 to 8 . Patients with GSs 7–8 were defined as GS high and those with GSs 0–6 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-activated GS-high patients had significantly shorter OS ( p = 0.041) compared with GS-low patients. (C) Analysis of gene coexpression in 1,084 samples of breast invasive carcinoma (TCGA, PanCancer Atlas) showed that NR2F1 positively correlated with the CREB1-repressed genes while negatively correlated with the CREB1-activated genes. (D) The 8 CREB1-repressed genes were scored similarly as described in (B). Patients with GSs 5–8 were defined as GS high, and those with GSs 0–4 as GS low. Kaplan-Meier analysis with log rank testing indicates the CREB1-repressed GS-high patients had significantly prolonged OS ( p = 0.040) compared with GS-low patients.

Article Snippet: Of these, 296 patients with both clinical outcome data and pre-treatment tumor RNAseq data were included in the analysis. mRNA expression levels (TPM) for AURKB, CDC20, CENPA, GGH, H2AC20, MND1, PRC1, and PSPH (CREB1-activated genes) as well as NR2F1, BTG2, FLRT2, SPRY1, NR4A2, GAS1, HOXA5, and STAT5B (CREB1-repressed genes) were obtained from the Human Protein Atlas ( https://www.proteinatlas.org ).

Techniques: Expressing